DBV Technologies Unveils Promising Phase 3 VITESSE Study Results at AAAAI 2026

DBV Technologies presented positive outcomes from its Phase 3 VITESSE study at the AAAAI 2026 Annual Meeting. The study focused on the VIASKIN® Peanut Patch for children with peanut allergies, aged 4 to 7. Results showed that 83% of the treated children increased their eliciting dose after 12 months, compared to 48% in the placebo group. Moreover, 60% witnessed an increase of at least two doses, contrasting with 23% in the placebo group.

The study achieved its primary endpoint with significant results: 46.6% of children on the VIASKIN Peanut Patch responded to the treatment versus 14.8% on placebo. This substantial difference confirms the treatment's potential efficacy. The patch was well-tolerated, primarily causing mild local reactions. DBV plans to submit a Biologics License Application to the FDA.